Senti Bio cuts 37% of staff; Evotec pockets $25M milestone from BMS; Novartis buys SanReno

08 Jan 2024

Gene TherapyAcquisitionCell TherapyImmunotherapy

Plus news about Oryzon Genomics, Cumulus Oncology, CureVac, Orion, Glykos Finland, Radiance Biopharma, Biocytogen, Marker Therapeutics and HilleVax: Senti Bio will lay off 37% of its staff: The cell and gene therapy developer will also scale back some R&D work to focus on its clinical programs . CEO Timothy Lu says these are “difficult but necessary steps” as it gathers proof-of-concept data for its gene circuit technology. The biotech expects to dose the first acute myeloid leukemia patient with its logic-gated cell therapy SENTI-202 in the second quarter of 2024. It will also continue to support a different candidate, targeted at glypican 3-expressing hepatocellular carcinoma glypican 3-expressing hepatocellular carcinoma, through a partnership in China. — Amber Tong

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

HilleVax, Inc.SANRENO THERAPEUTICS （HONG KONG）LIMITED

Glykos Finland Oy

[+8]

Indications

Acute Myeloid LeukemiaGPC3 Positive Hepatocellular Carcinoma

Targets

GPC3

Drugs

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.